Abstract:We conducted a retrospective cohort study of 88 patients with non‐small cell lung cancer (NSCLC) who initially received immune checkpoint inhibitor (ICI) combination therapy with chemotherapy to identify prognostic factors, including the combination of platelet count and neutrophil‐lymphocyte ratio (COP‐NLR). Our results suggested that baseline COP‐NLR was a prognostic factor, and a lower 3‐week COP‐NLR was associated with a good response to treatment. COP‐NLR is an important indicator for selecting patients who could benefit from the therapeutic efficacy of ICI combination therapy with chemotherapy. Background The relationship between the combination of platelet count and neutrophil‐lymphocyte ratio (COP‐NLR) and prognosis in patients with advanced non‐small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) combination therapy with chemotherapy remains unclear. Thus, we investigated prognostic factors, including the COP‐NLR, to identify patients who could benefit from the therapeutic efficacy of ICI combination therapy for advanced NSCLC. Furthermore, we evaluated the relationship between the COP‐NLR score during ICI combination therapy and treatment response. Methods We conducted a retrospective cohort study of 88 patients with NSCLC who initially received ICI combination therapy. The primary outcome was overall survival (OS). The prognostic factors were extracted using the Cox proportional hazards model. The relationship between COP‐NLR score at 3 weeks after starting ICI combination therapy and a good response (complete response [CR] and partial response [PR]) to treatment was analyzed using the chi‐square test. Results The median OS was 15.7 months. In the multivariable analysis, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2, distant metastatic sites ≥2, and baseline COP‐NLR scores of 1, 2 were extracted as significant poor prognostic factors. The proportion of patients with CR and PR in the 3‐week COP‐NLR score of 0 group was significantly higher than that in scores of 1, 2 group. Conclusions Baseline COP‐NLR, ECOG PS, and number of distant metastatic sites were prognostic factors in patients with NSCLC with ICI combination therapy. A lower 3‐week COP‐NLR was associated with a good response to treatment.

Combination of platelet count and neutrophil-lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival in metastatic advanced gastric cancer.

Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in systemic inflammation-related indi-cators in gastric cancer patients after radical resection

Prognostic Value of Neutrophil–Lymphocyte Ratio, Platelet–Lymphocyte Ratio, and Combined Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio in Stage IV Advanced Gastric Cancer

Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study

Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer

Changes in Neutrophil /lymphocyte Ratio and Platelet Count after Chemotherapy Correlate with Cheomtherapy Response and Predicition of Prognosis in Patients with Advanced Gastric Cancer.

Changes in Neutrophil/lymphocyte and Platelet/lymphocyte Ratios after Chemotherapy Correlate with Chemotherapy Response and Prediction of Prognosis in Patients with Unresectable Gastric Cancer

Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer.

Relationship between the combination of platelet count and neutrophil‐lymphocyte ratio and prognosis of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study

After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients.

The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.

Pretreatment platelet‐to‐lymphocyte ratio is associated with the response to first‐line chemotherapy and survival in patients with metastatic gastric cancer

Neutrophil-Lymphocyte Ratio As A Prognostic Marker For Chemotherapy In Advanced Lung Cancer

C-reactive Protein/albumin and Neutrophil/lymphocyte Ratios and Their Combination Predict Overall Survival in Patients with Gastric Cancer.

Neutrophil-Lymphocyte Ratio and Circulating Tumor Cells Counts Predict Prognosis in Gastrointestinal Cancer Patients

Combination of the Ratio Between Metastatic and Harvested Lymph Nodes and Negative Lymph Node Count As a Prognostic Indicator in Advanced Gastric Cancer: a Retrospective Cohort Study.

Pretreatment Neutrophil to Lymphocyte Ratio is Associated with Response to Therapy and Prognosis of Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy

Combined Neutrophil-to-Lymphocyte Ratio Score Is Associated With Chemotherapeutic Response and Predicts Prognosis in Patients With Advanced Pancreatic Cancer

Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients undergoing neoadjuvant chemotherapy: A systematic review and meta-analysis

Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients.

[Neutrophil-Lymphocyte Ratio As a Prognostic Factor in Gastric Cancer].